V67A.F COSMOS HEALTH NEW DL-01

Healthcare Pharmaceuticals Frankfurt Exchange
0.2064 EUR
Close of Nov 12, 2026
0.1471 0.6135
Market cap
EUR 20.8M
P/E
-
P/B
1.02x
ROE
-86.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is V67A.F undervalued?

Graham number

The Graham number of COSMOS HEALTH NEW DL-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

COSMOS HEALTH NEW DL-01 fundamental analysis

No fundamental analysis for COSMOS HEALTH NEW DL-01 yet.

COSMOS HEALTH NEW DL-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About COSMOS HEALTH NEW DL-01

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), H…

Full company profile